Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
|
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||
Total Research and Development - Licenses Acquired | $ 1,570 | $ 200 | $ 1,820 | $ 650 |
Mustang [Member] | ||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||
Total Research and Development - Licenses Acquired | 1,300 | $ 200 | 1,550 | $ 650 |
Oncogenuity | ||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||
Total Research and Development - Licenses Acquired | $ 270 | $ 270 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|